RFA-DA-22-031: HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $400,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 19, 2021.
From the official notice on Grants.gov, last changed July 6, 2021. Checked November 7, 2026.
- Award ceiling$400,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIDA
- Median yearly award$613,009
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-DA-22-031 were run by National Institute on Drug Abuse (NIDA, 7 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-22-031 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-DA-24-063 | July 19, 2023 | Closed February 1, 2024 | Closed |
Key dates
| Posted | July 6, 2021 |
|---|---|
| Deadline | October 19, 2021 |
| Archived by Grants.gov | November 24, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $613,009; it allows up to $400,000 per award.
- Most of the money in the 3 programs behind this notice (71% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to support research projects focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This FOA is part of the NIH Helping to End Addictions Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose. https://heal.nih.gov/research/medication-options
Funded under RFA-DA-22-031 so far
NIH funded 7 projects under RFA-DA-22-031 in fiscal 2022 to 2026, at 6 institutions. The median yearly award was $613,009.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Targeting Tiam1-mediated synaptic plasticity for the relief of opioid tolerance | University of Alabama at Birmingham | 2026 | $454,197 |
| Domain-specific inhibition of angiotensin-converting enzyme as a therapeutic strategy for opioid use disorders | University of Minnesota | 2026 | $523,500 |
| Endocannabinoid Targeting for Opioid Induced Respiratory Depression | University of Arizona | 2026 | $536,852 |
| Target Specificity of Tabernanthalog Treatment in Opioid Use Disorder | University of Alabama at Birmingham | 2026 | $535,758 |
| Brain-penetrant GPR88 agonists as novel therapeutics for opioid abuse | Sanford Burnham Prebys Medical Discovery Institute | 2026 | $581,970 |
| Transcriptomic single-cell profiling in breathing-specific parabrachial mu-opioid receptor neurons | Salk Institute for Biological Studies | 2026 | $668,659 |
| Ghrelin Deacylase as a Treatment for Opioid Polysubstance Abuse | University of Kentucky | 2025 | $506,678 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Who has won Arthritis, Musculoskeletal and Skin Diseases Research grants before
From fiscal 2021 to 2025, Arthritis, Musculoskeletal and Skin Diseases Research (93.846) awarded $2.6 billion across 2,897 grant awards, an average of $908,766 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 104 | $104 million |
| Brigham & Womens Hospital Inc | Massachusetts | 89 | $95.7 million |
| The Regents of the University of California, San Francisco | California | 84 | $93.3 million |
| The Washington University | Missouri | 88 | $72.4 million |
| Regents of the University of Michigan | Michigan | 73 | $68.0 million |
Who has won Research and Training in Complementary and Integrative Health grants before
From fiscal 2021 to 2025, Research and Training in Complementary and Integrative Health (93.213) awarded $575 million across 653 grant awards, an average of $880,790 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 15 | $25.9 million |
| The General Hospital Corporation | Massachusetts | 23 | $23.1 million |
| Duke University | North Carolina | 11 | $20.0 million |
| The Regents of the University of California, San Francisco | California | 16 | $15.2 million |
| Regents of the University of Minnesota | Minnesota | 13 | $15.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-22-031 still open?
No. It closed on October 19, 2021.
Who can apply for HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)?
Closed October 19, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $400,000 each.
Who has been funded under RFA-DA-22-031?
NIH RePORTER lists 7 projects funded under RFA-DA-22-031 in fiscal 2022 to 2026, at 6 institutions. The most were at University of Alabama at Birmingham, University of Minnesota, University of Arizona.
Who has won Research and Training in Complementary and Integrative Health grants before?
The largest recipients over five fiscal years were Yale Univ, The General Hospital Corporation, Duke University. The program made 653 awards worth $575 million in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)